Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons

Pharmaceutical Research

Volumn 27, Issue 5, 2010, Pages 920-932

  Kagan, Leonid ^a   Abraham, Anson K ^a   Harrold, John M ^a   Mager, Donald E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Allometry; Interferon; Nonlinear pharmacokinetics; Receptor binding; Target mediated drug disposition

Indexed keywords

ALPHA2A INTERFERON; BETA1A INTERFERON; INTERFERON BETA SERINE;

ALLOMETRY; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BODY WEIGHT; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG RECEPTOR BINDING; HUMAN; MEAN RESIDENCE TIME; MONKEY; MOUSE; NONHUMAN; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; PRIORITY JOURNAL; RAT; SIMULATION; SPECIES COMPARISON;

ALGORITHMS; ANIMALS; ANTIVIRAL AGENTS; AREA UNDER CURVE; BODY WEIGHT; CERCOPITHECUS AETHIOPS; HALF-LIFE; HUMANS; INTERFERON ALFA-2A; INTERFERON TYPE I, RECOMBINANT; INTERFERON-BETA; MICE; MODELS, STATISTICAL; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, INTERFERON; SPECIES SPECIFICITY;

EID: 77953287466     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0098-6     Document Type: Article

References (42)

1. Bekisz J, Schmeisser H, Hernandez J, Goldman ND, Zoon KC. Human interferons alpha, beta and omega. Growth Factors. 2004; 22: 243-251 (Pubitemid 40123402)
2. Samarajiwa SA, Wilson W, Hertzog PJ, Interferons TI. Genetics and structure. In: Meager A, editor. The interferons: characterization and application. Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA; 2006. p. 3-34.
3. Mogensen KE, Lewerenz M, Reboul J, Lutfalla G, Uze G. The type I interferon receptor: structure, function, and evolution of a family business. J Interferon Cytokine Res. 1999; 19: 1069-1098 (Pubitemid 29502774)
4. de Weerd NA, Samarajiwa, SA, Hertzog PJ. Type I interferon receptors: biochemistry and biological functions. J Biol Chem. 2007; 282: 20053-20057
5. Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Annu Rev Biochem. 1987; 56: 727-777
6. Fuchs D, Weiss G, Reibnegger G, Wachter H. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Grit Rev Clin Lab Sci. 1992; 29: 307-341 (Pubitemid 23011151)
7. Chiang J, Gloff CA, Soike KF, Williams G. Pharmacokinetics and antiviral activity of recombinant human interferon-beta ser 17 in African green monkeys. J Interferon Res. 1993; 13: 111-120 (Pubitemid 23121890)
8. Mager DE, Neuteboom B, Efthymiopoulos C, Munafo A, Jusko WJ. Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-betala in monkeys. J Pharmacol Exp Ther. 2003; 306: 262-270 (Pubitemid 36734381)
9. Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther. 1994; 56: 248-252
10. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001; 28: 507-532
11. Mager DE. Target-mediated drug disposition and dynamics. Biochem Pharmacol. 2006; 72: 1-10.
12. Mager DE, Jusko WJ. Receptor-mediated pharmacokinetic/ pharmacodynamic model of interferon-β la in humans. Pharm Res. 2002; 19: 1537-1543 (Pubitemid 35266560)
13. Segrave AM, Mager DE, Charman. SA, Edwards GA, Porter CJ. Pharmacokinetics of recombinant human leukemia inhibitory factor in sheep. J Pharmacol Exp Ther. 2004; 309: 1085-1092 (Pubitemid 38669695)
14. Woo S, Krzyzanski W, Jusko WJ. Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). J Pharmacokinet Pharmacodyn. 2007; 34: 849-868 (Pubitemid 350165278)
15. Adolph EF. Quantitative relations in the physiological constitutions of mammals. Science. 1949; 109: 579-585
16. Boxenbaum H, Ronfeld R. Interspecies pharmacokinetic scaling and the Dedrick plots. Am. J Physiol. 1983; 245: R768-775. (Pubitemid 14219457)
17. Dedrick RL, Animal scale-up. J Pharmacokinet Biopharm. 1973; 1: 435-461
18. Tang H, Mayersohn M. A novel model for prediction of human drug clearance by allometric scaling. Drug Metab Dispos. 2005; 33: 1297-1303 (Pubitemid 41196972)
19. Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res. 1991; 8: 1351-1359
20. Mahmood I. Interspecies scaling of protein drugs: prediction of clearance from animals to humans. J Pharm Sci. 2004; 93: 177-185 (Pubitemid 38081825)
21. Tang H, Mayersohn M. A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry. J Pharm Sci. 2006; 95: 1783-1799 (Pubitemid 44229585)
22. Woo S, Jusko WJ. Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. Drug Metab Dispos. 2007; 35: 1672-1678 (Pubitemid 47296063)
23. Buchwalder PA, Buclin T, Trinchard I, Munafo A, Biollaz J. Pharmacokinetics and pharmacodynamics of IFN-beta la in healthy volunteers. J Interferon Cytokine Res. 2000; 20: 857-866
24. Mager DE, Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res. 2005; 22: 1589-1596 (Pubitemid 41355898)
25. Kushnaryov VM, MacDonald HS, Sedmak JJ, Grossberg SE. Murine interferon-beta receptor-mediated endocytosis and nuclear membrane binding. Proc Natl Acad Sci U S A. 1985; 82: 3281-3285
26. Bino T, Edery H, Gertler A, Rosenberg H. Involvement of the kidney in catabolism of human leukocyte interferon. J Gen. Virol. 1982; 59: 39-45. (Pubitemid 12155883)
27. Bino T, Madar Z, Gertler A, Rosenberg H. The kidney is the main site of interferon degradation. J Interferon Res. 1982; 2: 301-308 (Pubitemid 13138655)
28. Rosenberg H, Madar Z, Gertler A, Rubinstein M, Bino T. The fate of [125I]-labeled human leukocyte-derived alpha interferon in the rat. J Interferon Res. 1985; 5: 121-127 (Pubitemid 15086876)
29. Interferon: The 50th Anniversary, Springer-Verlag, Berlin, 2007.
30. Sharma A, Ebling WF, Jusko WJ. Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J Pharm Sci. 1998; 87: 1577-1584 (Pubitemid 28559645)
31. Mager DE, Jusko WJ. Pharmacodynamic modeling of timedependent transduction systems. Clin Pharmacol Ther. 2001; 70: 210-216
32. Chiang J, Gloff CA, Yoshizawa CN, Williams GJ. Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin. Pharm Res. 1993; 10: 567-572 (Pubitemid 23113049)
33. Mager DE, Jusko WJ. Development of translational pharmacokinetic- pharmacodynamic models. Clin Pharmacol Ther. 2008; 83: 909-912
34. Mager DE, Woo S, Jusko WJ. Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet. 2009; 24: 16-24.
35. Cosson VF, Fuseau E, Efthymiopoulos C, Bye A, Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I: Interspecies allometric scaling. J Pharmacokinet Biopharm. 1997; 25: 149-167
36. Jolling K, Perez Ruixo JJ, Hemeryck A, Vermeulen A, Greway T. Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin. Eur J Pharm Sci. 2005; 24: 465-475 (Pubitemid 40387260)
37. Gloff C, Wills R. Pharmacokinetics and metabolism of therapeutic cytokines. New York: Plenum; 1992.
38. McKenna SD, Vergilis K, Arulanandam AR, Weiser WY, Nabioullin R, Tepper MA. Formation of human IFN-beta complex with the soluble type I interferon receptor IFNAR-2 leads to enhanced IFN stability, pharmacokinetics, and antitumor activity in xenografted SCID mice. J Interferon Cytokine Res. 2004; 24: 119-129 (Pubitemid 38253639)
39. Pepinsky RB, LePage DJ, Gill A, Ghakraborty A, Vaidyanathan S, Green M, et al. Improved pharmacokinetic properties of a polyethylene glycol-moditied form of interferon-beta-la with preserved in vito bioactivity. J Pharmacol Exp Ther. 2001; 297: 1059-1066 (Pubitemid 32472504)
40. Wills RJ, Dennis S, Spiegel HE, Gibson DM, Nadler PI. Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection. Clin Pharmacol Ther. 1984; 35: 722-727 (Pubitemid 14108762)
41. Wills RJ, Spiegel HE, Soike KF. Pharmacokinetics of recombinant alpha A interferon following I.V. infusion and bolus, I.M., and P.O. administrations to African green monkeys. J Interferon Res. 1984; 4: 399-409.
42. Lave T, Levet-Trafit B, Schmitt-Hoffmann AH, Morgenroth B, Richter W, Chou RC. Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations. J Pharm Sci. 1995; 84: 1285-1290